Trial Profile
A Phase IB Trial of Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 15 Feb 2024
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary) ; Vorolanib (Primary)
- Indications Brain metastases; Carcinoma; Gastric cancer; Gastrointestinal cancer; Liver cancer; Lung cancer; Oesophageal cancer; Small cell lung cancer; Solid tumours
- Focus Adverse reactions
- 01 Apr 2022 Results published in the Cancer Chemotherapy and Pharmacology
- 27 Jul 2020 Status changed from recruiting to discontinued due to low accrual.
- 23 Jan 2020 Planned number of patients changed from 56 to 36.